羟基喜树碱对人增生性瘢痕成纤维细胞胶原蛋白合成及Smad7表达的影响
|
摘要
目的:增生性瘢痕严重影响患者的美观及功能,但它的防治仍是烧伤整形外科学领域的重要难题。本研究通过观察羟基喜树碱对成纤维细胞胶原蛋白合成及细胞信号转导抑制子Smad7表达影响,以期了解羟基喜树碱抑制瘢痕作用机制。
方法:人增生性瘢痕标本取自本院整形患者,采用组织块法体外培养人增生性瘢痕成纤维细胞。(1)选取羟基喜树碱63,125,250,500,1000ng/ml共五个浓度梯度,采用ELISA法分别在24、48、72小时后检测细胞上清液中Ⅰ、Ⅲ型胶原蛋白量。(2) 125、250、500ng/ml浓度的羟基喜树碱作用瘢痕细胞24h后,采用逆转录-聚合酶链反应(RT-PCR)及蛋白印迹法(Western blot)分别观察Smad7 mRNA及蛋白的表达。
结果:(1)与对照组相比,实验组各浓度(63,125,250,500,1000ng/ml)羟基喜树碱均抑制增生性瘢痕成纤维细胞Ⅰ、Ⅲ型胶原蛋白的分泌,且随着药物浓度增加,抑制作用增强,与作用时间无明显相关。(2)实验组各浓度HCPT作用24小时后Smad7mRNA表达分别为0.350±0.037、0.431±0.054、0.616±0.038,与对照组(0.215±0.020)比较,差异有统计学意义(P<0.05)。Smad7蛋白表达分别为0.431±0.027、0.540±0.043、1.186±0.148,与对照组(0.280±0.033)比较,差异有统计学意义(P<0.05)。这说明,各浓度HCPT干预后增生性瘢痕成纤维细胞Smad7mRNA及蛋白表达均增强。其中,500ng/mL浓度组促表达作用最强。
结论:羟基喜树碱可通过抑制人增生性瘢痕成纤维细胞胶原蛋白的合成及促进瘢痕成纤维细胞Smad7的表达,来发挥抑制瘢痕形成的作用。
Goal: Hypertrophic scar (HS) is severely affected people,s appearance and function, but prevention and treatment of HS is still a difficult problem in the area of burn and plastic surgery medical research. In order to understand the mechanism of HCPT on treat scar, this study observed the effects of 10-hydroxycamptothecin (HCPT) on fibroblast collagen synthesis and the expression of cell signal transduction inhibitor Smad7,
Methods: HS obtained from patients who received plastic surgery, and then hypertrophic scar fibroblasts (HSFB) were cultured in vitro using tissue culture method. (1) HSFB was intervened by HCPT with various concentrations (63、125、250、500、1000ng/ml), the secretion of typeⅠ,Ⅲcollagen from HSFB were assayed with ELISA method after 24、48、72 hours. (2) HSFB was intervened by HCPT with various concentrations (125、250、500ng/ml) for 24 hours, then the expression of Smad7 mRNA was measured with RT-PCR and Smad7 protein was detected with western blot method.
Results : (1) Compared with the control group, HCPT with various concentrations (63、125、250、500、1000ng/ml) can inhibit the secreation of typeⅠ,Ⅲcollagen, and as the concentration increased, the effect of inhibition raised. But there is no significant relation with action time. (2) Compared with control group (0.215±0.020), the expression of Smad7mRNA in experiment groups is 0.350±0.037、0.431±0.054、0.616±0.038. There is significant difference between control group and experiment group (P<0.05). the expression of Smad7 protein in experiment groups is 0.431±0.027、0.540±0.043、1.186±0.148. And there is significant difference compared with control group (0.280±0.033). (P<0.05). These is indicated that hydroxycamptothecin could significantly increase Smad7 protein and mRNA expression in human hypertrophic scar fibroblasts,especially when its concentration at 500ng/mL.
Conclusion:Hydroxycamptothecin could inhibit collagen synthesis of HSFB, and enhanced the expression of Smad7 mRNA and protein, ,which has a role in the treatment of hypertrophic scars.
方法:人增生性瘢痕标本取自本院整形患者,采用组织块法体外培养人增生性瘢痕成纤维细胞。(1)选取羟基喜树碱63,125,250,500,1000ng/ml共五个浓度梯度,采用ELISA法分别在24、48、72小时后检测细胞上清液中Ⅰ、Ⅲ型胶原蛋白量。(2) 125、250、500ng/ml浓度的羟基喜树碱作用瘢痕细胞24h后,采用逆转录-聚合酶链反应(RT-PCR)及蛋白印迹法(Western blot)分别观察Smad7 mRNA及蛋白的表达。
结果:(1)与对照组相比,实验组各浓度(63,125,250,500,1000ng/ml)羟基喜树碱均抑制增生性瘢痕成纤维细胞Ⅰ、Ⅲ型胶原蛋白的分泌,且随着药物浓度增加,抑制作用增强,与作用时间无明显相关。(2)实验组各浓度HCPT作用24小时后Smad7mRNA表达分别为0.350±0.037、0.431±0.054、0.616±0.038,与对照组(0.215±0.020)比较,差异有统计学意义(P<0.05)。Smad7蛋白表达分别为0.431±0.027、0.540±0.043、1.186±0.148,与对照组(0.280±0.033)比较,差异有统计学意义(P<0.05)。这说明,各浓度HCPT干预后增生性瘢痕成纤维细胞Smad7mRNA及蛋白表达均增强。其中,500ng/mL浓度组促表达作用最强。
结论:羟基喜树碱可通过抑制人增生性瘢痕成纤维细胞胶原蛋白的合成及促进瘢痕成纤维细胞Smad7的表达,来发挥抑制瘢痕形成的作用。
Goal: Hypertrophic scar (HS) is severely affected people,s appearance and function, but prevention and treatment of HS is still a difficult problem in the area of burn and plastic surgery medical research. In order to understand the mechanism of HCPT on treat scar, this study observed the effects of 10-hydroxycamptothecin (HCPT) on fibroblast collagen synthesis and the expression of cell signal transduction inhibitor Smad7,
Methods: HS obtained from patients who received plastic surgery, and then hypertrophic scar fibroblasts (HSFB) were cultured in vitro using tissue culture method. (1) HSFB was intervened by HCPT with various concentrations (63、125、250、500、1000ng/ml), the secretion of typeⅠ,Ⅲcollagen from HSFB were assayed with ELISA method after 24、48、72 hours. (2) HSFB was intervened by HCPT with various concentrations (125、250、500ng/ml) for 24 hours, then the expression of Smad7 mRNA was measured with RT-PCR and Smad7 protein was detected with western blot method.
Results : (1) Compared with the control group, HCPT with various concentrations (63、125、250、500、1000ng/ml) can inhibit the secreation of typeⅠ,Ⅲcollagen, and as the concentration increased, the effect of inhibition raised. But there is no significant relation with action time. (2) Compared with control group (0.215±0.020), the expression of Smad7mRNA in experiment groups is 0.350±0.037、0.431±0.054、0.616±0.038. There is significant difference between control group and experiment group (P<0.05). the expression of Smad7 protein in experiment groups is 0.431±0.027、0.540±0.043、1.186±0.148. And there is significant difference compared with control group (0.280±0.033). (P<0.05). These is indicated that hydroxycamptothecin could significantly increase Smad7 protein and mRNA expression in human hypertrophic scar fibroblasts,especially when its concentration at 500ng/mL.
Conclusion:Hydroxycamptothecin could inhibit collagen synthesis of HSFB, and enhanced the expression of Smad7 mRNA and protein, ,which has a role in the treatment of hypertrophic scars.
引文
[1]. Monica C.T. B, Willem M V V, Magda M W U, et al. Prevention and curative management of hypertrophic scar formation[J]. Burns, 2008,7(16):1～13.
[2]. Civelek B, Celebioglu S. An unexpected complication of steroid use for the treatment of hypertrophic scar [J]. Ann Plast Surg. 2005 Feb;54(2):221～2.
[3]. Haverstock BD. Hypertrophic scars and keloids. Clin Podiatr Med Surg 2001 18(1):147-159
[4]. Willem M V V, Monica C T B, Magda M W U, et.al. Potential cellular and molecular causes of hypertrophic scar Formation[J]. Burns.2008,06 (20):1～15
[5].黄智龙,徐斌,蔡景龙.病理性瘢痕基因治疗的研究现状[J].徐州医学院学报,2009,29(8):557～560.
[6].吕远东,罗少军. TGF-β与病理性瘢痕[J].中华整形外科杂志, 2001,17 (2):117～119.
[7]. Jegffrey L. Wrana , Liliana Attisano. The Smad pathway[J]. Cytokine & Growth Factor Reviews 11 (2000) 5～13.
[8]. Kohei Miyazono. TGF-b signaling by Smad proteins[J]. Cytokine & Growth Factor Reviews 2000 (11) :15～22
[9]. Giovanni M, Francesco Pallone, Thomas T M. Smad7 in TGF-b-mediated negative regulation of gut in?ammation[J]. Trends in Immunology 2004,10(25):513～517.
[10]. Joan M, Joan S , and David W. Smad transcription factors[J]. Genes Dev.2005 19: 2783～2810
[11]. Wall ME ,Wani MC ,Cook CE , et al. Plant antitumor agents.Ⅰ.The isolation and structure of camptothecin , a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acumi nata[J]. J A m Chem Soc ,1966 ,88 :3888.
[12].陈晟,李玉艳,尤启冬.喜树碱类抗肿瘤药物耐药机制的研究进展[J].中国药物化学杂志. 2005,15(3):182～187.
[13].袁丹,容如滨,喻宗沉,等.抗肿瘤药10-羟基喜树碱的研究与应用进展[J].化学与生物研究工程, 2007, 24(12):9～11.
[14].徐丽婷,谢华.羟基喜树碱的药理作用及临床应用[J]. Herald of Medicine, 2002,5(22):302.
[15].郭茜如,种平等.喜树碱抑制滤过泡瘢痕化的临床研究[J].眼科研究,1995, 13(4):262～264.
[16].毕燕龙,容翱,胡桃舫,等.HCPT联合Ver防治试验性增生性玻璃体视网膜病变的初步研究[J].眼科新进展,2002,22(3):66～169.
[17].廖立新,潘登,陈刚泉,等.拓扑异构酶Ⅰ在人病理性瘢痕组织中的表达分析[J].中国组织工程研究与临床康复,2009,13(37):7291～7295.
[18].潘登,廖立新,陈刚泉.羟基喜树碱对病理性瘢痕成纤维细胞活性和凋亡的影响[J].中国现代药物应用,2008.09:26～28。
[19].司徒镇强,吴军正主编.细胞培养[M].兴界图书出版公司,1996.
[20]. Bian H N, Chen H D, Zhen S Y. Effects of continuons culture on the collagen synthesis of human hypertrophic-scar-derived fibroblast[J]. Chinese Journal of Experimental Surgery, 2007,24(2),161～166
[21].付小兵,程飚,盛志勇.创面愈合与瘢痕形成的分子学研究[J].中国临床康复杂志,2002, 6(4): 464～466.
[22].付小兵,程飚.进一步重视病理性瘢痕发生机制的研究[J].中国修复重建外科杂志,2005,19( 1) :1～5.
[23].郑健生,郑庆亦.瘢痕内注射曲安奈德致皮下色素沉着一例[J].中华烧伤杂志,21(5):387.
[24].姚红娜,黄丽妹,蒙秉新.皮损内注射得宝松治疗瘢痕疙瘩120例疗效观察[J].2003,3(4):486～487.
[25].陈浩宏,杨玲.消除瘢痕的药物研究[J].现代中西医结合杂志,2003,12(11):1121～1122.
[26].胡超,王元银.干扰素治疗病理性瘢痕的研究进展[J].重庆医学,2009,38(6):716～721
[27].周俐,石光清,邱娟.增生性瘢痕患者血清TNF—α检测的临床意义[J].放射免疫学杂志, 2008,4:329～320
[28].林序文,吴浩俊,张培华.中药有效成分治疗病理性瘢痕研究进展现代[J].中西医结合杂志2007 ,16 (26):3920～3922.
[29].刘德伍,李国辉,刘德明,等.粉防己碱对瘫痕成纤维细胞DNA和胶原合成的影响[J].中华烧伤杂志2001,17(4):222～224.
[30].袁志坚,何晓升,何文涓,等.粉防已碱对人增生性瘢痕成纤维细胞增殖及细胞周期的影响[J].中国生化药物杂志, 2008 ,29(2):44～46.
[31]. Chuan C, Shi R, Li X D, et al. Genistein inhibits proliferation and functions of hypertrophic scar fibroblasts[J]. Burns, 2008,3(11):1～9.
[32].王瑞国,王锦菊,余祥彬.积雪草甙对成纤维细胞DNA合成与胶原蛋白合成的影响[J].福建中医学院学报, 2001 ,11(2):41～42.
[33].祁少海,谢举临,利天增,等.积雪草甙对烧伤增生性瘢痕作用的实验研究[J].中华烧伤杂志2000,16(1):53～56.
[34].汤苏阳,蔡宝仁,徐获荣,等.苦参碱对增生性瘢痕成纤维细胞凋亡及相关调控蛋白表达的影响[J ].中华烧伤杂志, 2002 ,18(10) :299～301
[35].汤苏阳,蔡宝仁,马永福,等.苦参碱对人增生性瘢痕治疗作用的临床研究[J ].中国临床康复,2002 ,6 (14) :2066～2067
[36].孙钰,曹晓建,等.羟基喜树碱和丝裂霉素C预防椎板切除术后硬膜外粘连的研究[J].南京医科大学学报(自然科学版)2007,11.1213～1216
[37].沈瑞雄,石炳毅,莫春柏,等.羟基喜树碱诱导大鼠心脏移植免疫耐受机制的探讨[J].解放军医学杂志, 2002,27(10):858.
[38].石炳毅,莫春柏,钱叶勇,等.10-经基喜树碱和环饱素A诱导异基因大鼠.心脏移植受者免疫耐受的实验研究[J].中华实验外科杂志,2001,18(5):409～410.
[39].王瑞林,宋文广,付占昭,等.羟基喜树碱治疗肺癌脑转移疗效观察[J].中国癌症杂志,2002 12(6) :37～40.
[40].乔华,王艾蓉,林雁,等.羟基喜树碱治疗卵巢癌腹水近期疗效观察[J].肿瘤防治杂志,2001,8(4) :411～412
[41].孙元钰,赵晖,郭跃武等.草酸铂及羟基喜树碱联合亚叶酸钙和氟尿嘧啶治疗进展期结直肠癌的比较[J].世界华人消化杂志, 2005,14(19):1889～1894.
[42]. Joanna C L, Barbara M, Edwin A S, et al. The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis[J]. Arthritis Res 2001, 3:311～318.
[43]. Wen L W, Darlise D M. Increased susceptibility of spinal muscular atrophy fibroblaststo camptothecin-induced cell death[J]. Molecular Genetics and Metabolism. Volume 85, Issue 1, May 2005,85(1), 38～45.
[44]. Sun Y, Wang L, Cao X J,et al. The effect of 10-hydroxycamptothecine in preventing fibroblast proliferation and epidural scar adhesion after laminectomy in rats[J]. European Journal of Pharmacology, 2008, 593(28): 44～48.
[45].刘成海.肝脏胶原蛋白检测进展与评析[J].世界华人消化杂志, 2003,11(6):689～692.
[46].施珍,方宁远.自发性高血压大鼠血清脂联素水平及其对心肌胶原合成影响的研究[J].老年医学与保健,2007,13(5):277～283.
[47]. Francesco R, Shizuko T, George B G. Transcriptional regulation of the humanα2(I) collagen gene (COL1A2) an informative model system to study fibrotic diseases[J]. Matrix Biology 25 (2006) 365～372.
[48].武继祥,魏喜全,吴宗耀,等.增生性瘢痕胶原降解与形态学的观察[J].中华烧伤杂志, 2002,18(5): 296～298.
[49].曹治东,石崇荣,黄崇本,等.汉防已甲素对增生性瘢痕基质胶原酶活性的影响[J].中华整形烧伤杂志,2006,11(22):448～450。
[50].龚轶一,李小静,王明丽等.成纤维细胞分泌胶原蛋白与5-氟尿嘧啶的时间抑制效应[J].中国组织工程研究与临床康复,2007,11(6)1060～1062,1066.
[51].张选奋,李荟元,鲁开化,等.TGF-β或IFN-γ影响增生性瘫痕成纤维细胞增殖和胶原合成中PTK的作用.中华整形外科杂志,2005.1(21)36～39.
[52].于冬梅,陈天新,吕松岑,等.病理性瘢痕中Ⅰ、Ⅲ型前胶原mRNA及胶原蛋白表达与分布的研究[J].哈尔滨医科大学学报, 2003,37(6): 488～493.
[53]. Rashpal K B, Cristina M S, Tracy L M, et al. Molecular Aspects of Regulation of Collagen Gene Expression in Fibrosis[J]. Journal of Clinical Immunology, 2005, 25 (6): 592～603.
[54]. Huang T T, Wuerzberger, Davis SM. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events[J]. Biol Chem. 2000 275(13):9501～9509
[55]. Richard A R, Laura W S, Branko S,. NF-kappaB Inhibits Expression of the alpha1(I) Collagen Gene[J], DNA and Cell Biology. 1999, 18(10): 751-761.
[56]. Miltyk W, Kama E, Palka J A. Prolidase-independent mechanism of camptothecin- induced inhibition of collagen biosynthesis in cultured human skin fibroblasts[J]. Journal of iochemistry 2007, 141(2) 287～292 .
[57]. Gabriella L, Shinsuke T, Shu J C, et al. Targeted Disruption of TGF-β/Smad3 Signaling Modulates Skin Fibrosis in a Mouse Model of Scleroderma[J]. American Journal of Pathology, 2004,1(165):203～216.
[58]. Liu w,Wang DR,Can YL.TGF-beta:a fibrotic factor in Wound scarring and a potential target for anti-scarring gene therapy[J]. Curt Gene Ther, 2004,4(1):123～136.
[59]. Paul S, Gerard M, Louis D. TGF-β2 Activates Proliferative Scar Fibroblasts[J]. Journal of Surgical Research. 1999,82, 319～323
[60]. Xue W, Paul S, Lee L Q. Exogenous Transforming Growth Factorβ2 Modulates CollagenⅠand CollagenⅢSynthesis in Proliferative Scar Xenografts in Nude Rats[J]. Journal of Surgical Research. 1999,87: 194～200
[61]. Zhang K, Garner W, Cohen L, et al. Increased typeⅠandⅢcollagen and transforming growth factor-β1 mRNA and protein in hypertrophic burn scar[J].Invest Dermatol, 1995,104:750～754.
[62]. Shah M, Foreman D M, Ferguson M W J,et al. Control of scaring in adult wounds by neutralizing antibody to transforming growth factor beta. Lancent[J],1992,339:213～214.
[63]. Zhao J, Shi W, Chen H, et al. Smad7 and Smad6 differentially modulate transforming growth factor beta-induced inhibition of embryonic lung morphogenesis[J]. Biol Chem 2000,275: 23992～23997.
[64]. Ishisaki A, Yamato K, Hashimoto S, et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein-and activin-mediated growth arrest and apoptosis in B cells[J] Biol Chem, 1999,274:13637～13642.
[65]. Itoh S, Landstrom M, Hermansson A, et al. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7[J]. Biol Chem 1998,273:29195～29201.
[66]. Hanyu A, Ishidou Y, Ebisawa T, et al. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling[J]. Cell Biol 2001, 155: 1017～1027
[67]. Kavsak P, Rasmussen R K, Causing C G, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation[J]. Mol Cell, 2000,6: 1365～1375
[68]. Shi W, Sun C, He B, et al. GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor[J], Cell Biol, 2004,164:291～230.
[69]. Zhang S, Fei T, Zhang L, et al. Smad7 antagonizes TGF-βsignaling in the nucleus by interfering with functional Smad-DNA complex formation[J]. Mol Cell Biol, 2007, 27(12): 4488～99.
[70]. Terada Y, Hanada S, Nakao A, et al .Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-ob-structed kidney[J]. Kidney Int Suppl,2002 :61,94
[71].郝文科,余学清,窦献蕊等,上调Smad7表达对腹膜纤维化大鼠腹膜炎症细胞浸润及促炎症因子表达的影响[J]中华肾脏病杂志,2006,4(22):210～214
[72]. Dong C M, Zhu S k, Wang T. Deficient Smad7 expression: a putative molecular defect in scleroderma[J]. Proc. Natl. Acad. Sci. 2002, 99 (6), 3908～3913
[73]. Yu H Y, Oliver B, Ardeshir B,et al. Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring[J]. Journal of Plastic, Reconstructive & Aesthetic Surgery (2006) 59, 221～229
[74].潘姝,利天增,李叶扬,等.磷酸化Smad2和Smad7在增生性瘢痕成纤维细胞中的表达[J].中华烧伤杂志, 2006,4(22):133～134。
[75].潘登,廖立新,陈刚泉.羟基喜树碱对病理性瘢痕成纤维细胞活性和凋亡的影响[J].中国现代药物应用,2008.09:26～28。
[76]. Hirotaka Fukasawa, Tatsuo Yamamoto, Akashi Togawa. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice[J]. PNAS,2004 8, 101):8687～8692
[77].陈君毅,孙兴怀.转染Smad7基因的人眼球筋膜囊成纤维细胞Ⅰ型胶原蛋白及纤维连结蛋白的表达[J].中华眼科杂志,2007,43(2):124～128.
[78]. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice[J]. Clin Invest, 1999, 104～105.
[79]. Zimin Wang, Zhongyu Gao, Yi Shi, et al. Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts[J]. Journal of Plastic, Reconstructive & Aesthetic Surgery 2007, 60 ,1193～1199.
[1] Ten D P, Goumans M J, Itoh F, et al. Regulation of cell proliferation by Smad proteins. [J] Cell Physiol, 2002, 191(1): 1~16
[2] Wrana J L , Attisano L. The Smad pathway[J]. Cytokine and Growth Factor Rew. 2000, 11(1-2): 5~13.
[3] Thompson T B, Woodruff T K, Jardetzky T S. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions[J]. Embo J 2003,22:1555~1566.
[4]杨敏,黄海长,李惊子,等.转化生长因子β、结缔组织生长因子与肾纤维化[J].郧阳医学院学报. 2009,2 (29):62~64
[5] Massague J, Chen Y G.. Controlling TGF-βsignaling[J]. Genes Dev. 2000,14(6):627~ 644.
[6]姬洪全党耕町.转化生长因子β的生物学效应及其在骨折愈合过程中的作用[J].中华外科杂志,1998,8(36):40~43.
[7] Lyons R M , Kerioja J ,Mose H L. Prothelytic activation of latent transforming growth factorβfrom human platelets. [J] Biol Chem. 1988 ,263 :1659~1665.
[8] Rong H, Tang X M, ZhaoY et al. Postsurgical intraperitoneal exposure to glore powders modulatesin flammatory and immune related cytokinep roduction[J]. Wound Rep Reg, 1997,5:89~ 96.
[9]李清华,秦成勇,劳萍.转化生长因子β1在人肝纤维化组织中的表达及作用的探讨[J].世界华人消化杂志.2003,11(1):103~ 105
[10] Ignotz R A ,Massague J . Cell adhesion protein receptors as targets for transforming growth factor-βaction[J]. Cell ,1987 ,51 :189~ 197.
[11] Chen W, Fu X B, Sheng Z Y , Review of current progress in the structure and function of Smad proteins,[J] Chinese Medical Journal, 2002,115(3): 446~450 .
[12] Wu J W, Hu M, Chai J, et al. Crystal structure of a phosphorylated Smad2 recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling[J].Mol Cell 2001,8:1277~1289.
[13] Jegffrey L. Wrana , Liliana Attisano The Smad pathway[J], Cytokine & Growth Factor Reviews 11 (2000) 5~13.
[14] Kretzschmar M, Liu F, Hata A , et al. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase[J].Genes Dev. 1997,11:984~995.
[15] Caestecker M P, Yahata T, Wang D, et al. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain[J] Biol Chem 2000,275:2115~2122.
[16] Inman G J, Nicolas F J, Hill C S. Nucleocytoplasmic shuttling of Smads 2, 3,and 4 permits sensing of TGF-beta receptor activity[J]. Mol Cell 2002,10: 283~294
[17] Joan Massagué, Joan Seoane, and David Wotton, Smad transcription factors[J]. Genes Dev. 2005 19: 2783~2810
[18] Xu L, Massague J. Nucleocytoplasmic shuttling of signal transducers[J]. Nat Rev Mol Cell Biol. 2004,5:209~219.
[19] Zhao J, Shi W, Chen H ,et al. Smad7 and Smad6 differentially modulate transforming growth factor beta induced inhibition of embryonic lung morphogenesis[J]. Biol Chem 2000, 275: 23992~23997.
[20] Ebisawa T, Fukuchi M, Murakami G, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation[J]. Biol Chem 2001,276:12477~12480
[21] Atsuhito N, Ko O, Hideoki O, Smad7: a new key player in TGF-β-associated disease[J]. Trends in Molecular Medicine. 2002,8 (8): 361~363.
[22] Chen X, Weisberg E, Fridmacher V, et al. Smad4 and FAST-1 in the assembly of activin-responsive factor[J]. Nature, 1997, 389(6646): 85~89
[23] Itoh S. Itoh F. Goumans M J. Signaling of transforming growth factor-βfamily members through Smad proteins[J] Eur. J. Biochem. 2000, 267(24), 6954~6967.
[24] Hanai J. Chen L F. Kanno T. Interaction and functional cooperation of PEBP2/CBF with Smads[J]. Mol Cell Biol. 1999, 19(3): 1821~1830
[25] Hata A. Seoane J. Lagna G. OAZ uses distinct DNA- and protein-binding zincfingers in separate BMP-Smad and Olf signaling pathways[J]. Cell. 2000, 100(2): 229~240
[26] Yanagisawa J.Yanagi Y.Masuhiro Y Convergence of transforming growth factor-βand vitamin D signaling pathways on SMAD transcriptional coactivators[J]. Science, 1999, 283(5406): 1317~1321
[27] Hua X. Liu X. Ansari D O. Synergistic cooperation of TFE3 and smad proteins in TGF-βinduced transcription of the plasminogen activator inhibitor-1 gene[J]. Genes Dev. 1998, 12(19): 3084~3095
[28] Zhang W, Liu H T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells[J]. Cell Res, 2002, 12(1): 9~18
[29] Liberati N T. Moniwa M. Borton A J.et al. An essential role for Mad homology domain 1 in the association of Smad3 with histone deacetylase activity[J]. the American Society for Biochemistry and Molecular Biology, 2001,276(25): 22595~22603
[30] Zimmerman C M. Kariapper M S. Mathews L S. Smad proteins physically interact with calmodulin[J]. Biol Chem, 1998, 273(2): 677~680
[31] Choi B M,Kwak H J,Jun C D,et a1.Control of scarring in adult wounds using antisenge transforming growth factor-beta 1 oligodeoxynucleotides[J].Immunol Cell Biol, 1996,74(2):144~150.
[32] Whitby DJ, Ferguson M W. Imunohistochemical localization of growth factor in fetal wound healing[J].. Dev Bio1.1991;147(1):207~215
[33] Lanning D A, Mwomeh B C, Montanta S J, et al. TGF-betal alters the healing of cut aneousfe talex cisionalw ounds[J]. Pediatr Surg. 1999;34(5):695~700
[34] Krummel T M, Michna BA, Thomas B L, et a1.Transforming growth fator beta (TGF-β) induced fibrosis in a fetal wound model[J]. Pediatr Surg. 1988;23(7) :647~ 652
[35] Xue W, Paul S, , Lee L.Q ,Exogenous Transforming Growth Factorβ2 Modulates Collagen I and Collagen III Synthesis in Proliferative Scar Xenografts in Nude Rats1[J]. Journal of Surgical Research 87, (1999) 194 ~200
[36]潘姝,利天增,李叶扬,等,磷酸化Smad2和Smad7在增生性瘢痕成纤维细胞中的表达[J].中华烧伤杂志, 2006, 4(22):133 ~134。
[37] Haiyan Yu, Oliver B, Ardeshir B, Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring, Journal of Plastic[J]. Reconstructive & Aesthetic Surgery .2006, 59, 221~229
[38]唐冰,朱家源,朱斌,等.瘢痕疙瘩中TIEG1的高表达[J].生物化学与生物物理进展,2007,34(10):35~38
[39] Ashcroft G S,Yang X,Glick A B,et a1.Mice lacking Smad3 show accelerated wound healing and an impaired loca inflammatory response[J].Nat Cell Bid,1999,1(5):260~266
[40] Gao z,Wangz,Shi Y,et a1.Modulation of collagen synthesis in keloid fibroblasts by silencing Smad 2 with siRNA [J]. Plast Recorntr Surg,2006,118(6):1328~1337..
[41] Verrecchia F,Chu ML,Mauviel A.identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/ promoter transactivation approach[J]. Biol Chem。2001,276:17058~17062.
[42] Pan S,Li T Z,Li Y Y, Effect of asiaticoside on proliferation of scar fibroblasts and expression of phosphorylated Smad2 and Smad7[J]. Chinese Journal of Clinical Rehabilitation. 2005,9(10):230~232
[43]李璐,王继华,赵亚南,等.IFN-γ对大鼠创面愈合中Smad7表达的影响[J].中国美容医学. 2009,18 (2): 201~204.
[44]秦海洸,何长杰,唐汉钧,等.补虚祛瘀法对创面修复瘢痕重塑期Smad3介导的信号转导通路的影响[J].时珍国医国药.2009,20(1):84~85
[45] Wang Z M, Gao Z Y, Shi Y, Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts[J]. Journal of Plastic. Reconstructive & Aesthetic Surgery .2007, 60, 1193~1199
[46] Ironobu I. The Role of TGF-βSignaling in the Pathogenesis of Fibrosis in Scleroderma[J]. Archivum Immunologiae et Therapiae Experiment, 2002, 50: 325~331
[47] Yasuji M, Shu J C, John V, Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts[J]. 2003,7(48):1964 ~ 1978
[48] Chunming Dong, Shoukang Zhu, Goldschmidt-Clermont, et al, Deficient Smad7 expression: A putative molecular defect in scleroderma[J]. PNAS, 2002 , 19( 99):3908~3913.
[49] Mori Y, Chen S J, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts[J]. Arthritis Rheum 2003;48:1964~78.
[50] Chen S.J., Yuan W., LO S, et al. Interaction of Smad3 with proximal Smad-binding element of the humanα2(I) collagen gene promoter required for transcriptional activation by TGF-β[J] Cell. Physiol 2000,183, 381~392.
[51] Franck V , Alain Ml, Dominique F, Transforming growth factor-βsignaling through the Smad proteins:Role in systemic sclerosis[J]. Autoimmunity Reviews, 2006, (5): 563~569.
[52]高中玉.应用小干扰RNA抑制人瘢痕疙瘩Smad基因表达的实验研究[D].第二军医大学, 2006
[53] Pamella H M W, Marcos A C, Gabriela C, Deletion of bradykinin B1 receptor reduces renal fibrosis[J] .International Immunopharmacology, 2009, 9 (6): 653~657
[54] Maria S, Grethe N A, Kenneth N, et al. Suppressed signal transduction in the bronchial epithelium of patients with systemic sclerosis[J]. Respiratory Medicine, 2009, 103(2) 301-308.
[55]李英春,鲁开化,胡蕴玉,等.反义转化生长因子β_1基因转染对人瘢痕成纤维细胞的生物学作用的研究[D].第四军医大学, 1999。
[56] Gao X R, He X Y, Luo B, et al. Angiotensin II increases collagen I expression via transforming growth factor-beta1and extracellular signal-regulated kinase in cardiac fibroblasts [J] .European Journal of Pharmacology .2009, 606, 115 ~120.
[57] Hirotaka Fukasawa, Tatsuo Yamamoto, Akashi Togawa,Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice[J], PNAS,2004 8, 101):8687~8692
[58] Varela-Rey M, Montiel-Duarte C, Osés-Prieto J.A,p38 MAPK mediates the regulation ofα1(I) procollagen mRNA levels by TNF-αand TGF-βin a cell line of rat hepatic stellate cells[J]. Febs Letters, 2002, 528 (25): 133~138.
[2]. Civelek B, Celebioglu S. An unexpected complication of steroid use for the treatment of hypertrophic scar [J]. Ann Plast Surg. 2005 Feb;54(2):221～2.
[3]. Haverstock BD. Hypertrophic scars and keloids. Clin Podiatr Med Surg 2001 18(1):147-159
[4]. Willem M V V, Monica C T B, Magda M W U, et.al. Potential cellular and molecular causes of hypertrophic scar Formation[J]. Burns.2008,06 (20):1～15
[5].黄智龙,徐斌,蔡景龙.病理性瘢痕基因治疗的研究现状[J].徐州医学院学报,2009,29(8):557～560.
[6].吕远东,罗少军. TGF-β与病理性瘢痕[J].中华整形外科杂志, 2001,17 (2):117～119.
[7]. Jegffrey L. Wrana , Liliana Attisano. The Smad pathway[J]. Cytokine & Growth Factor Reviews 11 (2000) 5～13.
[8]. Kohei Miyazono. TGF-b signaling by Smad proteins[J]. Cytokine & Growth Factor Reviews 2000 (11) :15～22
[9]. Giovanni M, Francesco Pallone, Thomas T M. Smad7 in TGF-b-mediated negative regulation of gut in?ammation[J]. Trends in Immunology 2004,10(25):513～517.
[10]. Joan M, Joan S , and David W. Smad transcription factors[J]. Genes Dev.2005 19: 2783～2810
[11]. Wall ME ,Wani MC ,Cook CE , et al. Plant antitumor agents.Ⅰ.The isolation and structure of camptothecin , a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acumi nata[J]. J A m Chem Soc ,1966 ,88 :3888.
[12].陈晟,李玉艳,尤启冬.喜树碱类抗肿瘤药物耐药机制的研究进展[J].中国药物化学杂志. 2005,15(3):182～187.
[13].袁丹,容如滨,喻宗沉,等.抗肿瘤药10-羟基喜树碱的研究与应用进展[J].化学与生物研究工程, 2007, 24(12):9～11.
[14].徐丽婷,谢华.羟基喜树碱的药理作用及临床应用[J]. Herald of Medicine, 2002,5(22):302.
[15].郭茜如,种平等.喜树碱抑制滤过泡瘢痕化的临床研究[J].眼科研究,1995, 13(4):262～264.
[16].毕燕龙,容翱,胡桃舫,等.HCPT联合Ver防治试验性增生性玻璃体视网膜病变的初步研究[J].眼科新进展,2002,22(3):66～169.
[17].廖立新,潘登,陈刚泉,等.拓扑异构酶Ⅰ在人病理性瘢痕组织中的表达分析[J].中国组织工程研究与临床康复,2009,13(37):7291～7295.
[18].潘登,廖立新,陈刚泉.羟基喜树碱对病理性瘢痕成纤维细胞活性和凋亡的影响[J].中国现代药物应用,2008.09:26～28。
[19].司徒镇强,吴军正主编.细胞培养[M].兴界图书出版公司,1996.
[20]. Bian H N, Chen H D, Zhen S Y. Effects of continuons culture on the collagen synthesis of human hypertrophic-scar-derived fibroblast[J]. Chinese Journal of Experimental Surgery, 2007,24(2),161～166
[21].付小兵,程飚,盛志勇.创面愈合与瘢痕形成的分子学研究[J].中国临床康复杂志,2002, 6(4): 464～466.
[22].付小兵,程飚.进一步重视病理性瘢痕发生机制的研究[J].中国修复重建外科杂志,2005,19( 1) :1～5.
[23].郑健生,郑庆亦.瘢痕内注射曲安奈德致皮下色素沉着一例[J].中华烧伤杂志,21(5):387.
[24].姚红娜,黄丽妹,蒙秉新.皮损内注射得宝松治疗瘢痕疙瘩120例疗效观察[J].2003,3(4):486～487.
[25].陈浩宏,杨玲.消除瘢痕的药物研究[J].现代中西医结合杂志,2003,12(11):1121～1122.
[26].胡超,王元银.干扰素治疗病理性瘢痕的研究进展[J].重庆医学,2009,38(6):716～721
[27].周俐,石光清,邱娟.增生性瘢痕患者血清TNF—α检测的临床意义[J].放射免疫学杂志, 2008,4:329～320
[28].林序文,吴浩俊,张培华.中药有效成分治疗病理性瘢痕研究进展现代[J].中西医结合杂志2007 ,16 (26):3920～3922.
[29].刘德伍,李国辉,刘德明,等.粉防己碱对瘫痕成纤维细胞DNA和胶原合成的影响[J].中华烧伤杂志2001,17(4):222～224.
[30].袁志坚,何晓升,何文涓,等.粉防已碱对人增生性瘢痕成纤维细胞增殖及细胞周期的影响[J].中国生化药物杂志, 2008 ,29(2):44～46.
[31]. Chuan C, Shi R, Li X D, et al. Genistein inhibits proliferation and functions of hypertrophic scar fibroblasts[J]. Burns, 2008,3(11):1～9.
[32].王瑞国,王锦菊,余祥彬.积雪草甙对成纤维细胞DNA合成与胶原蛋白合成的影响[J].福建中医学院学报, 2001 ,11(2):41～42.
[33].祁少海,谢举临,利天增,等.积雪草甙对烧伤增生性瘢痕作用的实验研究[J].中华烧伤杂志2000,16(1):53～56.
[34].汤苏阳,蔡宝仁,徐获荣,等.苦参碱对增生性瘢痕成纤维细胞凋亡及相关调控蛋白表达的影响[J ].中华烧伤杂志, 2002 ,18(10) :299～301
[35].汤苏阳,蔡宝仁,马永福,等.苦参碱对人增生性瘢痕治疗作用的临床研究[J ].中国临床康复,2002 ,6 (14) :2066～2067
[36].孙钰,曹晓建,等.羟基喜树碱和丝裂霉素C预防椎板切除术后硬膜外粘连的研究[J].南京医科大学学报(自然科学版)2007,11.1213～1216
[37].沈瑞雄,石炳毅,莫春柏,等.羟基喜树碱诱导大鼠心脏移植免疫耐受机制的探讨[J].解放军医学杂志, 2002,27(10):858.
[38].石炳毅,莫春柏,钱叶勇,等.10-经基喜树碱和环饱素A诱导异基因大鼠.心脏移植受者免疫耐受的实验研究[J].中华实验外科杂志,2001,18(5):409～410.
[39].王瑞林,宋文广,付占昭,等.羟基喜树碱治疗肺癌脑转移疗效观察[J].中国癌症杂志,2002 12(6) :37～40.
[40].乔华,王艾蓉,林雁,等.羟基喜树碱治疗卵巢癌腹水近期疗效观察[J].肿瘤防治杂志,2001,8(4) :411～412
[41].孙元钰,赵晖,郭跃武等.草酸铂及羟基喜树碱联合亚叶酸钙和氟尿嘧啶治疗进展期结直肠癌的比较[J].世界华人消化杂志, 2005,14(19):1889～1894.
[42]. Joanna C L, Barbara M, Edwin A S, et al. The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis[J]. Arthritis Res 2001, 3:311～318.
[43]. Wen L W, Darlise D M. Increased susceptibility of spinal muscular atrophy fibroblaststo camptothecin-induced cell death[J]. Molecular Genetics and Metabolism. Volume 85, Issue 1, May 2005,85(1), 38～45.
[44]. Sun Y, Wang L, Cao X J,et al. The effect of 10-hydroxycamptothecine in preventing fibroblast proliferation and epidural scar adhesion after laminectomy in rats[J]. European Journal of Pharmacology, 2008, 593(28): 44～48.
[45].刘成海.肝脏胶原蛋白检测进展与评析[J].世界华人消化杂志, 2003,11(6):689～692.
[46].施珍,方宁远.自发性高血压大鼠血清脂联素水平及其对心肌胶原合成影响的研究[J].老年医学与保健,2007,13(5):277～283.
[47]. Francesco R, Shizuko T, George B G. Transcriptional regulation of the humanα2(I) collagen gene (COL1A2) an informative model system to study fibrotic diseases[J]. Matrix Biology 25 (2006) 365～372.
[48].武继祥,魏喜全,吴宗耀,等.增生性瘢痕胶原降解与形态学的观察[J].中华烧伤杂志, 2002,18(5): 296～298.
[49].曹治东,石崇荣,黄崇本,等.汉防已甲素对增生性瘢痕基质胶原酶活性的影响[J].中华整形烧伤杂志,2006,11(22):448～450。
[50].龚轶一,李小静,王明丽等.成纤维细胞分泌胶原蛋白与5-氟尿嘧啶的时间抑制效应[J].中国组织工程研究与临床康复,2007,11(6)1060～1062,1066.
[51].张选奋,李荟元,鲁开化,等.TGF-β或IFN-γ影响增生性瘫痕成纤维细胞增殖和胶原合成中PTK的作用.中华整形外科杂志,2005.1(21)36～39.
[52].于冬梅,陈天新,吕松岑,等.病理性瘢痕中Ⅰ、Ⅲ型前胶原mRNA及胶原蛋白表达与分布的研究[J].哈尔滨医科大学学报, 2003,37(6): 488～493.
[53]. Rashpal K B, Cristina M S, Tracy L M, et al. Molecular Aspects of Regulation of Collagen Gene Expression in Fibrosis[J]. Journal of Clinical Immunology, 2005, 25 (6): 592～603.
[54]. Huang T T, Wuerzberger, Davis SM. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events[J]. Biol Chem. 2000 275(13):9501～9509
[55]. Richard A R, Laura W S, Branko S,. NF-kappaB Inhibits Expression of the alpha1(I) Collagen Gene[J], DNA and Cell Biology. 1999, 18(10): 751-761.
[56]. Miltyk W, Kama E, Palka J A. Prolidase-independent mechanism of camptothecin- induced inhibition of collagen biosynthesis in cultured human skin fibroblasts[J]. Journal of iochemistry 2007, 141(2) 287～292 .
[57]. Gabriella L, Shinsuke T, Shu J C, et al. Targeted Disruption of TGF-β/Smad3 Signaling Modulates Skin Fibrosis in a Mouse Model of Scleroderma[J]. American Journal of Pathology, 2004,1(165):203～216.
[58]. Liu w,Wang DR,Can YL.TGF-beta:a fibrotic factor in Wound scarring and a potential target for anti-scarring gene therapy[J]. Curt Gene Ther, 2004,4(1):123～136.
[59]. Paul S, Gerard M, Louis D. TGF-β2 Activates Proliferative Scar Fibroblasts[J]. Journal of Surgical Research. 1999,82, 319～323
[60]. Xue W, Paul S, Lee L Q. Exogenous Transforming Growth Factorβ2 Modulates CollagenⅠand CollagenⅢSynthesis in Proliferative Scar Xenografts in Nude Rats[J]. Journal of Surgical Research. 1999,87: 194～200
[61]. Zhang K, Garner W, Cohen L, et al. Increased typeⅠandⅢcollagen and transforming growth factor-β1 mRNA and protein in hypertrophic burn scar[J].Invest Dermatol, 1995,104:750～754.
[62]. Shah M, Foreman D M, Ferguson M W J,et al. Control of scaring in adult wounds by neutralizing antibody to transforming growth factor beta. Lancent[J],1992,339:213～214.
[63]. Zhao J, Shi W, Chen H, et al. Smad7 and Smad6 differentially modulate transforming growth factor beta-induced inhibition of embryonic lung morphogenesis[J]. Biol Chem 2000,275: 23992～23997.
[64]. Ishisaki A, Yamato K, Hashimoto S, et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein-and activin-mediated growth arrest and apoptosis in B cells[J] Biol Chem, 1999,274:13637～13642.
[65]. Itoh S, Landstrom M, Hermansson A, et al. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7[J]. Biol Chem 1998,273:29195～29201.
[66]. Hanyu A, Ishidou Y, Ebisawa T, et al. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling[J]. Cell Biol 2001, 155: 1017～1027
[67]. Kavsak P, Rasmussen R K, Causing C G, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation[J]. Mol Cell, 2000,6: 1365～1375
[68]. Shi W, Sun C, He B, et al. GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor[J], Cell Biol, 2004,164:291～230.
[69]. Zhang S, Fei T, Zhang L, et al. Smad7 antagonizes TGF-βsignaling in the nucleus by interfering with functional Smad-DNA complex formation[J]. Mol Cell Biol, 2007, 27(12): 4488～99.
[70]. Terada Y, Hanada S, Nakao A, et al .Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-ob-structed kidney[J]. Kidney Int Suppl,2002 :61,94
[71].郝文科,余学清,窦献蕊等,上调Smad7表达对腹膜纤维化大鼠腹膜炎症细胞浸润及促炎症因子表达的影响[J]中华肾脏病杂志,2006,4(22):210～214
[72]. Dong C M, Zhu S k, Wang T. Deficient Smad7 expression: a putative molecular defect in scleroderma[J]. Proc. Natl. Acad. Sci. 2002, 99 (6), 3908～3913
[73]. Yu H Y, Oliver B, Ardeshir B,et al. Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring[J]. Journal of Plastic, Reconstructive & Aesthetic Surgery (2006) 59, 221～229
[74].潘姝,利天增,李叶扬,等.磷酸化Smad2和Smad7在增生性瘢痕成纤维细胞中的表达[J].中华烧伤杂志, 2006,4(22):133～134。
[75].潘登,廖立新,陈刚泉.羟基喜树碱对病理性瘢痕成纤维细胞活性和凋亡的影响[J].中国现代药物应用,2008.09:26～28。
[76]. Hirotaka Fukasawa, Tatsuo Yamamoto, Akashi Togawa. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice[J]. PNAS,2004 8, 101):8687～8692
[77].陈君毅,孙兴怀.转染Smad7基因的人眼球筋膜囊成纤维细胞Ⅰ型胶原蛋白及纤维连结蛋白的表达[J].中华眼科杂志,2007,43(2):124～128.
[78]. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice[J]. Clin Invest, 1999, 104～105.
[79]. Zimin Wang, Zhongyu Gao, Yi Shi, et al. Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts[J]. Journal of Plastic, Reconstructive & Aesthetic Surgery 2007, 60 ,1193～1199.
[1] Ten D P, Goumans M J, Itoh F, et al. Regulation of cell proliferation by Smad proteins. [J] Cell Physiol, 2002, 191(1): 1~16
[2] Wrana J L , Attisano L. The Smad pathway[J]. Cytokine and Growth Factor Rew. 2000, 11(1-2): 5~13.
[3] Thompson T B, Woodruff T K, Jardetzky T S. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions[J]. Embo J 2003,22:1555~1566.
[4]杨敏,黄海长,李惊子,等.转化生长因子β、结缔组织生长因子与肾纤维化[J].郧阳医学院学报. 2009,2 (29):62~64
[5] Massague J, Chen Y G.. Controlling TGF-βsignaling[J]. Genes Dev. 2000,14(6):627~ 644.
[6]姬洪全党耕町.转化生长因子β的生物学效应及其在骨折愈合过程中的作用[J].中华外科杂志,1998,8(36):40~43.
[7] Lyons R M , Kerioja J ,Mose H L. Prothelytic activation of latent transforming growth factorβfrom human platelets. [J] Biol Chem. 1988 ,263 :1659~1665.
[8] Rong H, Tang X M, ZhaoY et al. Postsurgical intraperitoneal exposure to glore powders modulatesin flammatory and immune related cytokinep roduction[J]. Wound Rep Reg, 1997,5:89~ 96.
[9]李清华,秦成勇,劳萍.转化生长因子β1在人肝纤维化组织中的表达及作用的探讨[J].世界华人消化杂志.2003,11(1):103~ 105
[10] Ignotz R A ,Massague J . Cell adhesion protein receptors as targets for transforming growth factor-βaction[J]. Cell ,1987 ,51 :189~ 197.
[11] Chen W, Fu X B, Sheng Z Y , Review of current progress in the structure and function of Smad proteins,[J] Chinese Medical Journal, 2002,115(3): 446~450 .
[12] Wu J W, Hu M, Chai J, et al. Crystal structure of a phosphorylated Smad2 recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling[J].Mol Cell 2001,8:1277~1289.
[13] Jegffrey L. Wrana , Liliana Attisano The Smad pathway[J], Cytokine & Growth Factor Reviews 11 (2000) 5~13.
[14] Kretzschmar M, Liu F, Hata A , et al. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase[J].Genes Dev. 1997,11:984~995.
[15] Caestecker M P, Yahata T, Wang D, et al. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain[J] Biol Chem 2000,275:2115~2122.
[16] Inman G J, Nicolas F J, Hill C S. Nucleocytoplasmic shuttling of Smads 2, 3,and 4 permits sensing of TGF-beta receptor activity[J]. Mol Cell 2002,10: 283~294
[17] Joan Massagué, Joan Seoane, and David Wotton, Smad transcription factors[J]. Genes Dev. 2005 19: 2783~2810
[18] Xu L, Massague J. Nucleocytoplasmic shuttling of signal transducers[J]. Nat Rev Mol Cell Biol. 2004,5:209~219.
[19] Zhao J, Shi W, Chen H ,et al. Smad7 and Smad6 differentially modulate transforming growth factor beta induced inhibition of embryonic lung morphogenesis[J]. Biol Chem 2000, 275: 23992~23997.
[20] Ebisawa T, Fukuchi M, Murakami G, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation[J]. Biol Chem 2001,276:12477~12480
[21] Atsuhito N, Ko O, Hideoki O, Smad7: a new key player in TGF-β-associated disease[J]. Trends in Molecular Medicine. 2002,8 (8): 361~363.
[22] Chen X, Weisberg E, Fridmacher V, et al. Smad4 and FAST-1 in the assembly of activin-responsive factor[J]. Nature, 1997, 389(6646): 85~89
[23] Itoh S. Itoh F. Goumans M J. Signaling of transforming growth factor-βfamily members through Smad proteins[J] Eur. J. Biochem. 2000, 267(24), 6954~6967.
[24] Hanai J. Chen L F. Kanno T. Interaction and functional cooperation of PEBP2/CBF with Smads[J]. Mol Cell Biol. 1999, 19(3): 1821~1830
[25] Hata A. Seoane J. Lagna G. OAZ uses distinct DNA- and protein-binding zincfingers in separate BMP-Smad and Olf signaling pathways[J]. Cell. 2000, 100(2): 229~240
[26] Yanagisawa J.Yanagi Y.Masuhiro Y Convergence of transforming growth factor-βand vitamin D signaling pathways on SMAD transcriptional coactivators[J]. Science, 1999, 283(5406): 1317~1321
[27] Hua X. Liu X. Ansari D O. Synergistic cooperation of TFE3 and smad proteins in TGF-βinduced transcription of the plasminogen activator inhibitor-1 gene[J]. Genes Dev. 1998, 12(19): 3084~3095
[28] Zhang W, Liu H T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells[J]. Cell Res, 2002, 12(1): 9~18
[29] Liberati N T. Moniwa M. Borton A J.et al. An essential role for Mad homology domain 1 in the association of Smad3 with histone deacetylase activity[J]. the American Society for Biochemistry and Molecular Biology, 2001,276(25): 22595~22603
[30] Zimmerman C M. Kariapper M S. Mathews L S. Smad proteins physically interact with calmodulin[J]. Biol Chem, 1998, 273(2): 677~680
[31] Choi B M,Kwak H J,Jun C D,et a1.Control of scarring in adult wounds using antisenge transforming growth factor-beta 1 oligodeoxynucleotides[J].Immunol Cell Biol, 1996,74(2):144~150.
[32] Whitby DJ, Ferguson M W. Imunohistochemical localization of growth factor in fetal wound healing[J].. Dev Bio1.1991;147(1):207~215
[33] Lanning D A, Mwomeh B C, Montanta S J, et al. TGF-betal alters the healing of cut aneousfe talex cisionalw ounds[J]. Pediatr Surg. 1999;34(5):695~700
[34] Krummel T M, Michna BA, Thomas B L, et a1.Transforming growth fator beta (TGF-β) induced fibrosis in a fetal wound model[J]. Pediatr Surg. 1988;23(7) :647~ 652
[35] Xue W, Paul S, , Lee L.Q ,Exogenous Transforming Growth Factorβ2 Modulates Collagen I and Collagen III Synthesis in Proliferative Scar Xenografts in Nude Rats1[J]. Journal of Surgical Research 87, (1999) 194 ~200
[36]潘姝,利天增,李叶扬,等,磷酸化Smad2和Smad7在增生性瘢痕成纤维细胞中的表达[J].中华烧伤杂志, 2006, 4(22):133 ~134。
[37] Haiyan Yu, Oliver B, Ardeshir B, Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring, Journal of Plastic[J]. Reconstructive & Aesthetic Surgery .2006, 59, 221~229
[38]唐冰,朱家源,朱斌,等.瘢痕疙瘩中TIEG1的高表达[J].生物化学与生物物理进展,2007,34(10):35~38
[39] Ashcroft G S,Yang X,Glick A B,et a1.Mice lacking Smad3 show accelerated wound healing and an impaired loca inflammatory response[J].Nat Cell Bid,1999,1(5):260~266
[40] Gao z,Wangz,Shi Y,et a1.Modulation of collagen synthesis in keloid fibroblasts by silencing Smad 2 with siRNA [J]. Plast Recorntr Surg,2006,118(6):1328~1337..
[41] Verrecchia F,Chu ML,Mauviel A.identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/ promoter transactivation approach[J]. Biol Chem。2001,276:17058~17062.
[42] Pan S,Li T Z,Li Y Y, Effect of asiaticoside on proliferation of scar fibroblasts and expression of phosphorylated Smad2 and Smad7[J]. Chinese Journal of Clinical Rehabilitation. 2005,9(10):230~232
[43]李璐,王继华,赵亚南,等.IFN-γ对大鼠创面愈合中Smad7表达的影响[J].中国美容医学. 2009,18 (2): 201~204.
[44]秦海洸,何长杰,唐汉钧,等.补虚祛瘀法对创面修复瘢痕重塑期Smad3介导的信号转导通路的影响[J].时珍国医国药.2009,20(1):84~85
[45] Wang Z M, Gao Z Y, Shi Y, Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts[J]. Journal of Plastic. Reconstructive & Aesthetic Surgery .2007, 60, 1193~1199
[46] Ironobu I. The Role of TGF-βSignaling in the Pathogenesis of Fibrosis in Scleroderma[J]. Archivum Immunologiae et Therapiae Experiment, 2002, 50: 325~331
[47] Yasuji M, Shu J C, John V, Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts[J]. 2003,7(48):1964 ~ 1978
[48] Chunming Dong, Shoukang Zhu, Goldschmidt-Clermont, et al, Deficient Smad7 expression: A putative molecular defect in scleroderma[J]. PNAS, 2002 , 19( 99):3908~3913.
[49] Mori Y, Chen S J, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts[J]. Arthritis Rheum 2003;48:1964~78.
[50] Chen S.J., Yuan W., LO S, et al. Interaction of Smad3 with proximal Smad-binding element of the humanα2(I) collagen gene promoter required for transcriptional activation by TGF-β[J] Cell. Physiol 2000,183, 381~392.
[51] Franck V , Alain Ml, Dominique F, Transforming growth factor-βsignaling through the Smad proteins:Role in systemic sclerosis[J]. Autoimmunity Reviews, 2006, (5): 563~569.
[52]高中玉.应用小干扰RNA抑制人瘢痕疙瘩Smad基因表达的实验研究[D].第二军医大学, 2006
[53] Pamella H M W, Marcos A C, Gabriela C, Deletion of bradykinin B1 receptor reduces renal fibrosis[J] .International Immunopharmacology, 2009, 9 (6): 653~657
[54] Maria S, Grethe N A, Kenneth N, et al. Suppressed signal transduction in the bronchial epithelium of patients with systemic sclerosis[J]. Respiratory Medicine, 2009, 103(2) 301-308.
[55]李英春,鲁开化,胡蕴玉,等.反义转化生长因子β_1基因转染对人瘢痕成纤维细胞的生物学作用的研究[D].第四军医大学, 1999。
[56] Gao X R, He X Y, Luo B, et al. Angiotensin II increases collagen I expression via transforming growth factor-beta1and extracellular signal-regulated kinase in cardiac fibroblasts [J] .European Journal of Pharmacology .2009, 606, 115 ~120.
[57] Hirotaka Fukasawa, Tatsuo Yamamoto, Akashi Togawa,Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice[J], PNAS,2004 8, 101):8687~8692
[58] Varela-Rey M, Montiel-Duarte C, Osés-Prieto J.A,p38 MAPK mediates the regulation ofα1(I) procollagen mRNA levels by TNF-αand TGF-βin a cell line of rat hepatic stellate cells[J]. Febs Letters, 2002, 528 (25): 133~138.